skip to Main Content

Welcome

Celebrating 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

ADVOCACY UPDATES

Changes To E/M Codes Beginning On January 1st

Effective January 1, 2021, the Centers for Medicare & Medicaid (CMS) finalized significant changes to…

read more

Additional COVID-19 Relief Up in the Air

House Speaker Nancy Pelosi (D-CA) and Treasury Secretary Steven Mnuchin appeared to be moving closer…

read more

CY 2021 Physician Fee Schedule Proposed Rule Summary

On August 3, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

03/15/21: 2021 Annual Meeting Crowdsourcing
Learn more

03/15/21: Call for Proposals
Learn more

04/01/21: Fellow Exam Application Deadline
Learn more

06/01/21: Research Grant Cycle
Learn more

06/26/21: Membership Application Deadline to be eligible for AAOA Member rate for the 2021 Basic Course

07/15/21: Call for Scientific Papers

09/01/21: Membership Application Deadline to be voted in at the 2021 Annual Meeting

12/01/21: Research Grant Cycle
Learn more

EDUCATION

Don't miss the opportunity to curate content you need now conveniently in your own office or home! The content will only be available until March 25th!

NEW YEAR, SAME PANDEMIC

Looking for insights as you focus on 2021 and practice growth? Still struggling with some of the reboot challenges from COVID? AAOA is re-releasing core content from its summer Pandemic course to help give you access to content you need now. Register now for the great way to gain insights, earn up to 13 hrs CME, and help meet your maintenance of certification (MOC) requirements.

JUST THE BASICS

Do you have new staff and need help training them on the core concepts of allergy diagnosis and management in ENT? In your practice reboot, are you reconsidering your practice set up or considering adding allergy to your practice? Are you looking for great review tools for you and your staff?

To help you we are offering time-limited access to our core allergy education library to give you and your staff the tools you need to get up to speed or refresh on the key concepts in allergy diagnosis and management. Register today and earn up to 8.75 hrs of CME (MOC eligible).

IFAR

IFAR Impact Factor: 2.454

aaoaf-ifar

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Now Available

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

New Year, Same Pandemic
January 25-March 25 | On-Demand
Learn More and Register

Just the Basics
January 25-March 25 | On-Demand
Learn More and Register

2021 Basic Course in Allergy & Immunology
On-demand Mid-June Live Stream Targeted For July 8-11 | Virtual
Learn More and Register

USP 797 Online Module
Learn More and Register

2021 AAOA Annual Meeting
Pre-launch Mid-September
Live Stream Starting on Oct 16 | Virtual
Learn More

News and Updates

A Pivotal New Publication on the Role of Biologics

A team led by AAOA Education Coordinator Cecelia Damask, DO, FAAOA, and AAOA President (2018-2019)…

read more

CMS Coding 2021 – AAOA Zoomcast

A brief summary of the CMS Coding 2021 – AAOA Zoomcast Series: Just In Time…

read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PATIENT CORNER

Allergic Reactions Related to Covid-19 Vaccinations in Allergic Patients

Joint Statement by the American Academy of Otolaryngology–Head and Neck Surgery (AAO–HNS) and the American Academy of Otolaryngic Allergy (AAOA)

Allergic reactions are uncommon and anaphylaxis following vaccines is rare, occurring at a rate of approximately one per million doses for many vaccines.1,2,3 In order to prevent allergic reactions, it is important to identify individuals at increased risk by obtaining a history of allergy to previous vaccinations and vaccine components that might indicate an underlying hypersensitivity. Acute allergic reactions following vaccinations might be caused by the vaccine antigen, residual animal protein, antimicrobial agents, preservatives, stabilizers, or other vaccine components.4

Those administering vaccinations, including Pfizer-BioNTech COVID-19 vaccine and Moderna vaccine (mRNA COVID vaccines), need to be familiar with identifying and managing immediate-type allergic reactions, including anaphylaxis.

Immediate-immunoglobulin E (IgE)–mediated (type 1) immune reactions, such as anaphylaxis, usually occur within minutes of parenteral administration and involve specific IgE interactions with discrete antigens.5,6 Rapid recognition and initiation of treatment are necessary to prevent possible progression to respiratory failure or cardiovascular collapse. The CDC is recommending monitoring patients for 15-30 minutes post injection.

Epinephrine and equipment for managing an airway should be available for immediate use.7 The first and most important therapy in anaphylaxis is epinephrine. There are NO absolute contraindications to epinephrine in the setting of anaphylaxis. All anaphylactic reactions should be managed immediately with IM epinephrine as the first line treatment.

A history of severe allergic reactions not related to vaccines or injectable medications—such as allergies to food, pet, venom, environmental, or latex—is not a contraindication, and these patients can still get vaccinated. People with a history of allergies to oral medications or a family history of severe allergic reactions, or who might have a milder allergy to vaccines (no anaphylaxis) — may also still get vaccinated.8

In general, a history of a severe allergic reaction to a vaccine should be considered a contraindication to additional doses of the same vaccine.9 If a patient experiences a severe allergic reaction after getting the first dose of the mRNA COVID-19 vaccine, they should not get the second shot and referral for evaluation to possibly determine the component responsible, before making decisions regarding administration of the additional doses of the same vaccine or other vaccines that have the same components should be considered.

The recommendations below are based on best knowledge to date but may change at any time, pending new information and further guidance from the CDC or FDA.

  1. Individuals with common allergies to medications, foods, inhalants, venoms, and latex are no more likely than the general public to have an allergic reaction to the mRNA COVID-19 vaccines.
  2. The mRNA COVID-19 vaccines should be administered in a healthcare setting where anaphylaxis can be recognized and treated. Vaccination providers should have appropriate medications and equipment—such as epinephrine and equipment for managing an airway. All anaphylactic reactions should be managed immediately with IM epinephrine as the first line treatment.
  3. All people who receive a mRNA COVID-19 vaccine should be monitored on-site after receiving their dose. People with a history of severe allergic reactions should be monitored for 30 minutes after getting the vaccine. All others should be monitored for 15 minutes after getting the vaccine.
  4. According to the CDC, if a patient has a severe allergic reaction after getting the first shot, they should not receive the second shot. Additionally, the CDC notes patients who experience a severe allergic reaction should receive a referral for evaluation to possibly determine the component responsible for the reaction.
  5. The mRNA COVID-19 vaccines should not be administered to individuals with a known history of a severe allergic reaction to any component of the vaccine. The specific vaccine component causing the anaphylaxis has not been identified. Polyethylene glycol (PEG) is one of the vaccine’s ingredients and has been known to cause anaphylaxis.10,11,12 PEG is used as an inactive ingredient in some drugs. PEG is also used as a bowel prep for colonoscopy procedures and as a laxative.
  6. Data related to risk in individuals with a history of allergic reactions to other previous vaccinations and/or idiopathic anaphylaxis is very limited and evolving. A clinical decision to administer either of the COVID-19 vaccines should be undertaken by the physician or other provider administering the vaccine using their professional judgment and in consultation with the patient, balancing the benefits and risks associated with taking the vaccine.
  7. Recommendations are to defer vaccination for 90 days after receiving convalescent plasma or monoclonal antibody treatment for COVID-19.

Coadministration with Other Vaccines
Given the lack of data on the safety and efficacy of mRNA COVID-19 vaccines administered simultaneously with other vaccines, the mRNA COVID-19 vaccine series should be administered alone, with a minimum interval of 14 days before and after administration with any other vaccines.8 Allergen immunotherapy (SCIT, SLIT-tablets, and SLIT-aqueous) as well as biologics, such as omalizumab and dupilumab, are not considered vaccines and do not need to be held for 14 days before and 14 days after mRNA COVID-19 vaccines. Expert opinion recommends not administering subcutaneous immunotherapy injections or biologics on the same day as the mRNA vaccine and no dose adjustment for sublingual forms (both tablets and aqueous) of immunotherapy.

Immunodeficiency
The mRNA COVID-19 vaccines are not live vaccines and thus can be administered to immunocompromised patients. Providers should inform these immunocompromised patients of the possibility of a diminished immune response to the mRNA COVID-19 vaccine.

Biologics/monoclonal Antibodies
Dupilumab has several indications for use, most notable among which for otolaryngologists is as an add-on maintenance treatment in adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).13 According to its package insert, the use of live vaccines should be avoided with dupilumab. Dupilumab has not been studied with live vaccines. The two currently FDA approved COVID-19 vaccinations are both non-live, mRNA vaccines. There are currently no live-attenuated virus vaccines in clinical trials.14

A phase 2 DBPC study assessing the immune response to non-live vaccines in atopic dermatitis adults on dupilumab showed that antibody responses to both meningococcal polysaccharide vaccine and tetanus vaccine were similar in both placebo-treated and dupilumab-treated subjects.

Omalizumab similarly has several indications for use, including as an add-on maintenance treatment for nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

Dupilumab and omalizumab are classified as immunomodulator medications (medications that act by directly changing the behavior of the immune system).15 There is no evidence that dupilumab nor omalizumab have immunosuppressive effects.

This table is published on the CDC’s webpage, “Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States.”

For more information and updates, please also visit the CDC’s webpage, “COVID-19 Vaccines and Severe Allergic Reactions.”

1 Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815-820. DOI: 10.1542/peds.112.4.815

2 McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016; 137(3):868-878.

3 Dreskin et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organization Journal 2016; 9:32.

4 Grabenstein JD. Clinical management of hypersensitivities to vaccine components. Hospital Pharmacy. 1997;32:77-87.

5 Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126(3):477-480.e471-442. DOI: 10.1016/j.jaci.2010.06.022

6 Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130(1):25-43. DOI: 10.1016/j.jaci.2012.04.003

7 Kroger A, Atkinson W, Pickering L. General immunization practices. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines. 6th ed. China: Elsevier Saunders; 2013:88-111.

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/allergic-reaction.html accessed 12/22/2020

9 Wood RA, Berger M, Dreskin SC, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008;122(3):e771-777. DOI: 10.1542/peds.2008-1002.

10 Sellaturay P, Nasser S, Ewan P. Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis). J Allergy Clin Immunol Pract. 2020 Oct 1:S2213-2198(20)31007-2. doi: 10.1016/j.jaip.2020.09.029. Epub ahead of print. PMID: 33011299.

11 Stone CA, Liu Y, et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol Pract. 2019; 7(5): 1533–1540.

12 Wylon, K., Dölle, S. & Worm, M. Polyethylene glycol as a cause of anaphylaxis. J Allergy Asthma Clin Immunol. 12, 67 (2016).

13 Dupixent (dupilumab) Prescribing Information, Regeneron and Sanofi-Genzyme, 2020.

14 Chung Y, Beiss V, Fiering S, et al. COVID-19 Vaccine Frontrunners and Their Nanotechonology Design. 2020; 14(10): 12522-12537.

15 www.aaaai.org/conditions-and-treatments/drug-guide/immunomodulator-allergy

Back To Top